Extended Data Fig. 4: In vitro and in vivo activity of CM-272 and CDDP in BC cells.
From: Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression
a, Cell proliferation of BC cells (RT112, 5637 and UMUC1) after treatment with CM-272 alone or in combination with CDDP, showing a synergistic effect (combination index <1 as defined by Chou and Talalay36). The asterisks show the P values of a one-tailed Mann–Whitney U-test (*P < 0.05). n = 3 independent experiments. The error bars indicate the s.d. b, RT112 cells (5 × 106) were subcutaneously implanted in the flanks of nude mice (5 per group). When tumors reached 150–250 mm3, mice were treated intraperitoneally with CM-272 (5 mg kg−1 5 d per week), CDDP (6 mg kg−1 once a week) or both compounds for 2 weeks. Tumor volume was related to baseline volume before treatment. Data are represented as the mean ± s.e.m. P values were determined by a one-sided Mann–Whitney U-test. c, H&E-stained and immunohistochemistry images showing the expression of the cited proteins or histone marks in tumor xenografts corresponding to the cited treatment groups. The representative images of at least 6 independent samples obtained from 3–6 different animals are shown. Scale bars, 150 µm. d, Immunoblot showing the expression of the cited proteins or histone marks in tumor xenografts corresponding to the cited treatment groups. Tubulin and total H3 levels were used to normalize loading. A representative example of two independent experiments including three independent samples from each group of mice is shown. Full uncropped blots are available as.
